Hepatitis B virus reactivation during direct-acting antiviral treatment of chronic hepatitis C: A hidden danger of an otherwise major success story-Reference-Cited by-同舟云学术

Hepatitis B virus reactivation during direct-acting antiviral treatment of chronic hepatitis C: A hidden danger of an otherwise major success story

Published:2017-05-18 Issue:1 Volume:66 Page:4-6
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Perrillo Robert P.¹

Affiliation:

1. Hepatology Division; Baylor University Medical Center; Dallas TX

Publisher

Wiley

Subject

Hepatology

Reference15 articles.

1. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions;Bini;Hepatology,2010

2. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection;Sato;J Hepatol,1994

3. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus coinfected patients;Raimondo;Hepatology,2006

4. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir;Collins;Clin Infect Dis,2015

5. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents;Wang;Clin Gastroenterol Hepatol,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A DESCRIPTIVE STUDY TO ASSESS THE KNOWLEDGE AND ATTITUDE OF STAFF NURSES REGARDING PREVENTION OF HEPATITIS –B;GLOBAL JOURNAL FOR RESEARCH ANALYSIS;2022-08-15

2. An update on direct antiviral agents for the treatment of hepatitis C;Expert Opinion on Pharmacotherapy;2021-05-11

3. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies;Virus Research;2018-03

4. Hepatitis C: from discovery to cure;ISBT Science Series;2018-02-09

5. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in “special populations”;Liver International;2018-02